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1 
ABSTRACT 40 
 41 
Background: Cancer diagnostics and surgery have been disrupted by the response of 42 
healthcare services to the COVID-19 pandemic. Progression of cancers during delay will 43 
impact on patient long-term survival.  44 
Methods: We generated per-day hazard ratios of cancer progression from observational 45 
studies and applied these to age-specific, stage-specific cancer survival for England 2013-46 
2017. We modelled per-patient delay of three months and six months and periods of 47 
disruption of one year and two years. Using healthcare resource costing, we contextualise 48 
attributable lives saved and life-years gained from cancer surgery to equivalent volumes of 49 
COVID-19 hospitalisations. 50 
Findings: Per year, 94,912 resections for major cancers result in 80,406 long-term survivors 51 
and 1,717,051 life years gained. Per-patient delay of three/six months would cause 52 
attributable death of 4,755/10,760 of these individuals with loss of 92,214/208,275 life-53 
years. For cancer surgery, average life-years gained (LYGs) per patient are 18.1 under 54 
standard conditions and 17.1/15.9 with a delay of three/six months (an average loss of 55 
0.97/2.19 LYG per patient). Taking into account units of healthcare resource (HCRU), surgery 56 
results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under 57 
standard conditions and 2.12/1.97 RALYGs following delay of three/six months. For 94,912 58 
hospital COVID-19 admissions, there are 482,022 LYGs requiring of 1,052,949 HCRUs. 59 
Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 60 
LYG and 0.46 RALYGs.  61 
Interpretation: Modest delays in surgery for cancer incur significant impact on survival.  62 
Delay of three/six months in surgery for incident cancers would mitigate 19%/43% of life-63 
years gained by hospitalisation of an equivalent volume of admissions for community-64 
acquired COVID-19. This rises to 26%/59% when considering resource-adjusted life-years 65 
gained. To avoid a downstream public health crisis of avoidable cancer deaths, cancer 66 
diagnostic and surgical pathways must be maintained at normal throughput, with rapid 67 
attention to any backlog already accrued.  68 
 69 
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2 
INTRODUCTION 72 
Following the first case reports in Hubei province, China in late 2019, a pandemic of COVID-73 
19 coronavirus was declared by the World Health Organisation in March 2020. Whilst 74 
COVID-19 causes minimal or mild illness in most, a small but appreciable proportion of 75 
individuals require oxygen therapy and often admission to an Intensive Care Unit (ICU). The 76 
ensuing unprecedented pressure on hospital wards and ICUs has necessitated rapid 77 
redeployment of staff and capacity towards the management of COVID-19 cases with 78 
deprioritisation of non-emergency clinical services, including diagnostics and elective 79 
specialist surgery. Concurrently, lockdown of the population has impacted dramatically on 80 
presentation and referral of symptomatic patients from primary into secondary care[1].  81 
 82 
For patients with cancer, delay of surgery has the real potential to increase the likelihood of 83 
metastatic disease, with some patients’ tumours progressing from being curable (with near 84 
normal life expectancy) to non-curable (with limited life expectancy)[2]. The situation has 85 
been further exacerbated by recent safety concerns regarding aerosol generation from 86 
endoscopy, cystoscopy and surgery[3, 4].  87 
 88 
Current projections indicate that COVID-19-related disruption may well last for 18 months 89 
or more, until there is either long term effective containment in the population or large-90 
scale vaccination. To inform healthcare prioritisation and resource allocation, we have 91 
examined the impact on cancer outcomes of different periods of delay of cancer surgery 92 
with disruption extending over variable time periods, comparing resource-weighted 93 
outcomes to hospital management of COVID-19 patients.  94 
  95 
3 
METHODS 96 
Data sources 97 
Number and age-specific five-year net survival of cancer patients that had potentially 98 
curative surgical resections for non-haematological malignancies between 2013 and 2017 99 
were obtained from Public Health England National Cancer Registration Service (NCRAS)[5]. 100 
As well as cancer stage at diagnosis for each cancer type, breast tumour receptor data 101 
allowed subtyping of these cancers as ER+ HER2-, HER+ (any), ER- HER2-, and other.  102 
Estimates for nosocomial infection rates, median duration of hospital stay for each cancer 103 
type, staffing of theatres, ICU and surgical wards were based on information from three 104 
large UK surgical oncology centres. Patterns of administration of adjuvant systemic anti-105 
cancer therapy (SACT) were based on oncologist-reviewed standard practice guidance[6]. 106 
ICU COVID-19 mortality, distribution by age, and duration of stay and proportion referred 107 
into ICU were obtained from ICNARC and data from hospitalised UK cases[7, 8]. Due to lack 108 
of UK data, data from Wuhan was used as the basis for the age distribution of community 109 
infection, age-specific likelihoods of admission from community to hospital, and mortality 110 
rates for non-ICU COVID-19 patients [9, 10] (Supplementary Table 1).   111 
 112 
Analysis 113 
Impact of COVID-associated delay on cancer outcomes 114 
We used published data from studies examining the impact on overall survival from delay in 115 
cancer surgery to estimate per day hazard ratios (HRs) associated with delay for different 116 
cancers (the “Fatality HR”)  [11-21]. We had sufficient data to generate Fatality HRs for three 117 
tumour types and assigned these to other tumours, based on comparability of 5-year 118 
survival as low (>90%) moderate (50-90%) or high (<50%) progressiveness tumours[5]. 119 
Because we were unable to identify any suitable observational data for tumours of high 120 
progressiveness (e.g. oesophageal, gastric), we applied the Fatality HR from tumours of 121 
moderate progressiveness; this is likely to be a conservative assumption (Supplementary 122 
Table 2).   123 
By accounting for COVID-related post-surgical mortality and changes in SACT, we adjusted 124 
five-year net survival figures for each cancer for surgical patients under standard care to 125 
estimate current five-year net survival.  To model outcomes of surgery post-delay, we apply 126 
to standard five-year net survival, the Fatality HR relating to the specified number of days of 127 
4 
delay, again including COVID-related post-surgical mortality. Based on estimates from a UK 128 
surgical oncology centre, supported by the literature, we applied a current per day rate of 129 
nosocomial infection of 5%.  Assuming improvement in cold protocols, we modelled 130 
reduction in this rate over time. We estimated COVID-associated surgical mortality based on 131 
per day rate of nosocomial infection, operation-specific duration of post-surgical admission, 132 
and age-specific mortality from infection. We estimated COVID-19 associated mortality for 133 
SACT administration, based on per day rate of nosocomial infection, the frequency of SACT 134 
scheduling, increased risk associated with immunosuppression, and age-specific mortality 135 
from infection. We assumed, where standard-of-care, that SACT offers a uniform survival 136 
benefit (5% in Stage 1, 7.5% in Stage 2 and 10% in Stage 3) and administration would only 137 
continue where this benefit exceeds COVID-related mortality.  138 
We used mean life-expectancies per 10-year age-group to calculate life years gained, 139 
averaged per patient. We examined reduction in overall survival and life years gained (LYG), 140 
comparing surgery under standard care, current conditions and post-delay, by cancer type 141 
and by age and stage. Using 2013-2017 surgical workload data, we calculated across all 142 
adult cancers examined, the total number of deaths and life years lost attributable to delay. 143 
To address possible scenarios, we considered per-patient delay of up to six-months, and 1- 144 
and 2-year periods of disruption.  145 
 146 
COVID-19 outcome 147 
To compare life years associated with timely cancer surgery with that afforded by 148 
hospitalisation of COVID-19 patients, we modelled a volume of community-ascertained 149 
COVID-19 infection resulting in an equivalent volume of hospital admissions to cancer 150 
surgeries (Supplementary Table 1).  151 
 152 
Resource 153 
We analysed healthcare resource units (HCRU) focused specifically on frontline medical and 154 
nursing staff, where one HCRU is one 12-hour shift of direct nursing or medical care. We up-155 
weighted for shifts from healthcare workers of high-salary (senior doctors) and/or of current 156 
scarcity (anaesthetists, ICU nurses). We calculated HCRUs per patient using estimated 157 
staffing ratios for theatres, ICU and ward care and operation-specific data for theatre hours, 158 
ICU stay and ward days from oncology centres.  159 
5 
Details of assumptions and parameter estimates are detailed in Table 1 and Supplementary 160 
Table 1. Analyses were performed using STATA (version 15) and transcribed to Excel, to 161 
provide a full visibility of parametrisation, model outputs, and opportunity for the reader to 162 
customise parameters (Supplementary Materials).  163 
 164 
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6 
RESULTS 166 
Impact of surgical delay on survival for different cancers 167 
The greatest rates of deaths arise following even modest delays to surgery in aggressive 168 
cancers, with over 30% reduction in survival at six months and over 17% reduction in 169 
survival at three months for patients with stage 2 or 3 cancers of the bladder, lung, 170 
oesophagus, ovary, liver, pancreas and stomach (Table 2, Supplementary Table 3, 171 
Supplementary Materials). Accounting for nosocomial COVID-19 infection, for cancers with 172 
a relatively good overall prognosis, delay of surgery by three months had a minimal impact 173 
on survival: <1% for all Stage 1 ER+ and HER2+ breast cancers, for example. In older patients 174 
(>70 years), for early stage colorectal, kidney and ER+ breast cancers, the current impact on 175 
survival of COVID-related mortality exceeded the impact of three or even six months delay 176 
(Table 2, Supplementary Table 3).  177 
 178 
For a high proportion of solid cancers, survival at five years is generally considered to be 179 
equivalent to cure. Predicated on this assertion, we considered life-years gained adjusting 180 
for resource (resource adjusted life years (RALYGs)). Perhaps unsurprisingly, most benefit is 181 
afforded in younger age groups for operations that are shorter with no associated ICU 182 
requirement. For example, trans-urethral resection of stage 1 bladder cancers affords on 183 
average 23.4 RALYG per patient age 30-39, whereas cystectomy for stage 2 bladder cancer is 184 
only associated with 1.2 RALYGs in that age group (Supplementary Table 4). In the context 185 
of prioritisation, avoidance of a six-month delay restitutes on average 4.1 RALYGs in the 186 
former group, compared to 0.7 in the latter (Table 3, Supplementary Table 5). Wide local 187 
excision for breast cancer has low resource requirement and therefore confers substantial 188 
RALYGs, even in good prognosis subtypes. 189 
  190 
Impact of surgical delay on cancer survival combined across cancer types 191 
Each year, 94,912 surgical resections for common invasive adult cancer types are performed 192 
in England, with 80,406 of those patients surviving their cancer at five years. A surgical delay 193 
of three months across all incident solid tumours over one year would incur 4,755 excess 194 
deaths, escalating to 10,760 excess deaths for a six-month delay. This includes at six 195 
months, attributable deaths of 2,980 for colorectal cancer 1,439 for lung cancer and 804 for 196 
breast cancer (Figure 1). 197 
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 198 
For a high proportion of solid cancers, five-year survival is generally considered to be 199 
equivalent to cure. Predicated on this assertion, across all cancers a delay of three months 200 
in treatment would lead to a reduction of 92,214 life-years and for six months’ reduction of 201 
208,275 life years (Table 3). Prior to the COVID-19 crisis, each year cancer surgery was 202 
directly responsible for 1,717,051 LYGs. This represents on average 18·1 LYG per patient, 203 
which markedly reduces to 17·1 with three months’ delay and to 15·9 with six months’ 204 
delay. Cancer surgery per year requires 764,765 units of healthcare resource. Assuming this 205 
to be unchanged by delay, this affords on average 2.25 RALYG per patient under standard 206 
conditions, reducing to 2.12 with three months’ delay and 1.97 with six months of delay, an 207 
average loss of 0.12 and 0.27 RALYGs, respectively, per patient. 208 
 209 
Resource comparison for outcomes afforded by cancer surgery and COVID-19 210 
management 211 
For contextualisation, we compare the impact of cancer surgery delay to hospital care for 212 
patients with community-acquired COVID-19 infection. COVID-19 ICU admission for those 213 
aged 40-49 yielded on average 27.5 LYG and 0.8 RALYG. Those aged >80 years admitted to 214 
ICU benefit by on average 2.1 LYG and 0.06 RALYG. For non-ICU admission, average benefit 215 
is 9.3 LYG and 1.5 RALYG for those aged 40-49 and 1.4 LYG and 0.2 RALYG for those aged 216 
>80 years (Supplementary Materials). These estimates are inherently conservative as they 217 
do not take into account the impact on life expectancy of the excess comorbidities 218 
associated with many hospitalised COVID-19 cases. 219 
 220 
COVID-19 community-acquired infection of 683,083 individuals would result in 94,912 221 
hospital admissions (i.e. the equivalent number to number of annual admissions for cancer 222 
surgery). For these 94,912 admissions, 16,135 will require ICU (critical cases) and 78,777 will 223 
not require ICU (severe cases). 1,052,949 units of healthcare resource are required in total 224 
and there are 15,587 deaths, 25,752 attributable lives saved, and 482,022 attributable LYGs 225 
(8,241 deaths/7,894 attributable lives saved/223,227 LYGs for ICU admissions, 7,346/ 226 
17,858/ 258,795 for non-ICU). This represents on average 5.08 LYG and 0.46 RALYG per 227 
hospitalised COVID-19 patient. 228 
 229 
8 
It is therefore noteworthy, that a delay of surgery by six months results in 208,275 lost life-230 
years for an annual quota of surgical patients: this equates to 43% of the total 482,022 life-231 
years gained from hospitalisation of an equivalent number of community-acquired COVID-232 
19 cases. This rises to 59% when adjusted for differences in resource (RALYGs). 233 
 234 
Sensitivity Analysis 235 
The outcomes from the model were mostly sensitive to changes in the Fatality HR for the 236 
per-day delay: varying this by ±8% (1SD) caused the average LYG with a six-month delay to 237 
range from 15.7-16.1, and attributable LY lost by 2.00-2.39.  Sensitivity analysis for other 238 
parameters is shown in Supplementary Table 2.   239 
 240 
  241 
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DISCUSSION 242 
We provide estimates derived from reported surgical outcomes to quantify the impact on 243 
survival of delay of cancer treatment, within the parameters of the assumptions of the 244 
model.  245 
 246 
Implications for healthcare planning  247 
For aggressive cancers, our analysis demonstrates that even short delays (three months) 248 
have a significant impact on patient survival. However, even for cancers of comparatively 249 
favourable prognosis, a delay of six months will result in significant summed attributable 250 
deaths as many of these cancers are common. Delay will also result in tumours being more 251 
advanced, meaning not only is survival poorer, but that the upstaged cancers will be more 252 
costly to treat both in terms of surgery and/or chemotherapy. Furthermore, resource 253 
requirements (for example, ICU stay) are dramatically higher for the many who will 254 
inevitably present as emergencies such as with obstruction, perforation or acute bleeding of 255 
the gastrointestinal tract[22]. 256 
 257 
Critical to mitigating cancer deaths is recognition that delay or bottleneck may arise at any 258 
point in the linear patient journey from (i) self-presentation of the symptomatic patient to 259 
primary care, (ii) primary care review and referral into secondary care (iii) diagnostic 260 
investigation, and (iv) surgery (or radiotherapy) with curative intent. Alongside any ‘bulge’ in 261 
accumulated cases will be the normal stream of incident cancer presentations. In the face of 262 
prolonged stress, it will be challenging to provide extra capacity to address these bulges 263 
alongside standard demands. In the short term, to avoid knock-on delays, immediate 264 
diversion of supra-normal resource volumes are required to process the backlog of cases 265 
that will have accrued in the initial months of the pandemic, in which referrals, 266 
investigations, and surgeries have been reduced by up to 80%[1].  In the medium-long term 267 
(over the next 3-24 months), avoidance of delay to cancer surgery should be of the highest 268 
priority: urgent attention is required to ensure sufficient resourcing for standard capacity of 269 
all pathway elements in primary care, cancer diagnostic, and surgical. 270 
 271 
Delay in cancer surgery will have a highly deleterious health and economic impact. For the 272 
most part, the surgery will still be required (and may be more complex and costly) but 273 
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results in rapid diminution resultant life-years gained and resource-adjusted life-years. 274 
Comparing equivalent-sized hospital populations adjusted for resource, the health impact of 275 
delaying cancer surgery for six months will approximate 60% of health gains of 276 
hospitalizations for community acquired COVID-19 infection.  We need to consider 277 
resourcing in the likely event of sizeable requirement for COVID-19 management for a 278 
sustained period of time, potentially up to two years. Although large facilities may be 279 
built/repurposed for COVID-19 management, these facilities are competing for the same 280 
fixed pool of healthcare workers that provide care for treating non-COVID-19 disease.  281 
 282 
Currently, where the rate of nosocomial infection is high, for older groups in particular, 283 
surgery and/or SACT may in the short-term offer more risk than benefit (see Supplementary 284 
Materials).  Active focus is required to establish ‘cold’ sections of the healthcare system, 285 
with rigorous protocols for staff screening and shielding protocols. This will serve to 286 
minimise nosocomial acquisition and mortality from COVID-19, to protect staff, and also to 287 
provide reassurance to the public regarding uptake of diagnostics and surgery for cancer.  288 
 289 
Urgent review by professional bodies is required regarding best protection of their staffing 290 
groups, and guidance on surgical and diagnostic practice commensurate with the true 291 
risks[3]. 292 
 293 
Implications for prioritisation amongst cancer patients 294 
Given an accrued backlog of cases and ongoing tight competition for resources, decisions 295 
regarding surgical prioritisation may be required for a number of years, with capacity 296 
varying geographically and temporally. Recognising its limitations regarding assumptions 297 
and parameters, we propose a model that provides a rational approach by which to 298 
evaluate across patients of different ages, tumour types, and stages, the benefit and 299 
resource implications of their cancer surgery. We highlight in our model those age-stage 300 
groups for which COVID-related mortality currently exceeds survival benefit for surgery 301 
and/or SACT. Whilst these and other groups for whom benefit is marginal will be the most 302 
rationale to delay, they will nevertheless require monitoring and surgery downstream. 303 
Longitudinal planning, monitoring of progression, dynamic re-prioritisation, and capacity-304 
planning will inevitably be highly challenging.  305 
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 306 
 307 
Broader and International relevance 308 
While we have used data for England, cancer survival is broadly similar across most 309 
economically developed countries, so the impact of delay per tumour is broadly applicable 310 
across Europe. However, variation in incidence of cancer, life expectancy and population 311 
age structure mean that predictions regarding total case numbers and life-years gained and 312 
lost are more difficult to extrapolate, even when scaling for relative size of reference 313 
population. 314 
Whilst customised for surgical delay due to the COVID-19 pandemic, this model could 315 
readily be adapted to quantify the impact of surgical delay due to other causes.  316 
 317 
Limitations  318 
As with any model-based analysis, our predictions are predicated on the validity of 319 
assumptions and estimates used for parameterisation. While we have made use of 320 
observational data, our approach simplifies the complexity of cancer progression and is 321 
solely survival-focused. For healthcare planning, a more elaborate model capturing stage-322 
shifting may offer additional utility.  We base our analysis on survival data from 2013-17; for 323 
some tumour types, standard-of-care and survival has evolved since this time.  Our 324 
modelling of the benefit of SACT is simplistic as the scheduling, benefits and 325 
immunosuppressive consequences vary by chemotherapy regimen. Whilst we have included 326 
in our model the impact withholding of SACT if nosocomical infection risk is high, we have 327 
not modelled additional reduction in survival from delays in administration of adjuvant 328 
therapy.  Mortality from nosocomial COVID-19 infection during surgical admission or 329 
attendance for chemotherapy is based on a uniform per-day risk of infection: these may 330 
vary between institutions. While our resourcing analysis deliberately focuses on the 331 
requirement for the direct medical and nursing staff who most limit healthcare provision, 332 
we acknowledge it does not capture other ‘costs’ incurred in hospital care, primary care, 333 
and social care.  334 
Our model of COVID-19 admissions is limited by availability of detailed individual-level UK 335 
data, in particular for non-CCU hospital admissions; this model is also conservative in regard 336 
of disregarding impact of co-morbidities on life expectancy. 337 
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 338 
Further research 339 
Within our current approach, we only estimate the effects of a specified period of per-340 
patient delay. Contemporaneous data for NHS activity offers the prospect of developing 341 
dynamic models to predict the impact of (i) differential prioritisation of patient groups, (ii) 342 
different patterns of re-presentation of ‘accumulated’ cases alongside incident cases, and 343 
(iii) varying release of bottlenecks in primary care, diagnostics, and surgery. Evaluation is 344 
also important for the alternative management approaches being adopted, such as 345 
radiotherapy with curative intent where surgery is gold-standard or a priori hormonal 346 
treatment for prostate and ER-positive breast cancers. For any strategies involving 347 
deliberate delay to surgery, models for re-staging and dynamic re-prioritisation are 348 
essential. We have focused on the impact to surgery with curative intent; analyses are also 349 
required to quantify the impact on mortality of changes to life-extending chemo- and radio-350 
therapy for patients with Stage 4 disease.  351 
 352 
CONCLUSION 353 
 354 
Compared to COVID-19 management, cancer surgery is highly impactful in regard to life-355 
years gained per resource expended. Delay in diagnosis and surgery cause exponential 356 
burden of attributable mortality. The COVID-19 pandemic has placed unprecedented strain 357 
on health care provision. It is highly plausible that surges of population infection, lock-358 
downs, resource competition, bottlenecks, and back-logs could recur over the next two 359 
years. Supra-normal capacity is required to manage backlogs of accumulated cancer cases 360 
alongside ongoing incident cases. To avoid a deferred public health crisis of unnecessary 361 
cancer deaths, urgent ringfencing of substantial resources is required.  362 
 363 
  364 
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LEGENDS FOR FIGURES 365 
 366 
Figure 1: Impact from 6-months delay lasting one year for all solid cancers analysed and six 367 
common cancer types in England expressed in a: Attributable deaths  b: Life years Lost 368 
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Highlights 405 
• Lockdown and re-deployment due to the COVID-19 pandemic is causing significant 406 
disruption to cancer diagnosis and management. 407 
• 3-month delay to surgery across all Stage 1-3 cancers is estimated to cause >4,700 408 
attributable deaths per year in England. 409 
• The impact on life years lost of 3-6 month to surgery for Stage 1-3 disease varies 410 
widely between tumour types. 411 
• Strategic prioritisation of patients for diagnostics and surgery has potential to 412 
mitigate deaths attributable to delays. 413 
• The resource-adjusted benefit in avoiding delay in cancer management compares 414 
favourably to admission for COVID-19 infection. 415 
 416 
  417 
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 COMPONENT OF 
MODEL 
ELEMENTS DATA SOURCE COMMENT Reference/specific values 
Life years lost 
due to delay in 
surgery 
Proportion of 
patients 
surviving after 
surgery 
5 year survival 
rates for cancer 
surgery in 
England  
Age, site, and stage-
specific 5-year cancer 
survival in individuals 
in whom major 
resection was 
performed 
PHE NCRAS[4] 
Decrease in 
survival due to 
delay in 
treatment 
Observational 
studies of 
increased death 
rate due to delay 
in treatment 
Hazard ratio for 
increase in death rate 
for each day delay in 
treatment based on 
estimates from 
literature, applied to 
standard survival 
rates.  Applied to 
tumours depending 
on tumour 
aggressiveness 
Cancer progressiveness 
based on 5y survival: 
Low: >90%,  
Moderate: 50-90% 
High: <50% 
 
Per day Hazard ratio for 
fatality [10-20]: 
Low: 0.0030,  
Mod: 0.0056 
High: 0.0056 
COVID-related 
post-surgical 
mortality.   
SACT-related 
mortality  
Nosocomial 
infection rate  
Based on literature, 
estimate from clinical 
site data 
5 % per day[29] 
Mortality from 
COVID-infection 
Age-specific data 
from international 
series 
0-39 y 0.2% 
30-39 y 0.2% 
40-49 y 0.4% 
50-59 y 1.3% 
60-69 y  3.6% 
70-79 y 8.0% 
80+ y 14.8% 
 
Survival benefit 
from SACT 
Expert clinical 
interpretation of 
literature  
Stage 1: 5% 
Stage 2: 7.5% 
Stage 3: 10% [30] 
Increase in 
COVID-related 
mortality due to 
SACT 
Based on UK and 
international 
literature 
2-fold [7, 8] 
Life-expectancy 
after survival 
General 
population mean 
life-expectancies 
per 10 year age-
band 
Expected remaining 
life years in treated 
group based on 
proportion who 
survive after 
treatment (with and 
without delay) 
ONS Life Tables[31] 
Healthcare 
resourcing 
Duration of 
operation, ICU 
and inpatient 
ward stay 
Data from UK 
surgical oncology 
centres 
Calculated as 
Healthcare Resource 
Unit (HCRUs) of direct 
clinical care.  1 HCRU= 
one 12 hour 
medical/nursing shift  
 
Staffing ratios in 
theatre, wards, 
ICU 
Table 1:  Summary of sources for parameters estimates for cancer surgical model (see 
Supplementary Table 1 for full description) 
 
 
  
 Stage 30-39 y 40-49 y 50-59 y 60-69 y 70-79 y 80+ y 
Bladder 1 15.8% 15.8%* 26.3% 18.4% 21.9% 23.8% 
2 36.0% 35.9% 32.7% 31.9% 29.0% 28.6% 
3 35.9% 35.8%* 34.8% 34.1% 32.4% 29.3% 
Breast (ER+, HER2-) 
 
1 1.5% 0.6% -0.3% -1.5% -3.2% -3.1% 
2 5.9% 2.8% 2.4% 0.7% -1.3% -5.6% 
3 13.4% 8.2% 9.2% 9.2% 9.1% 2.5% 
Breast (ER-, HER2-) 1 6.2% 4.3% 5.4% 2.3% 0.5% 4.1% 
2 13% 12.2% 11.3% 10.0% 12.7% 14.0% 
3 18.2% 19.8% 19.4% 18.5% 18·2% 16.0%
Breast (HER2+) 1 0·4% 0·9% 1.0% 0.5% -1.7% 3.5% 
2 4.2% 3.1% 3.4% 3.0% 3.3% 6.5% 
3 11.3% 7.0% 9.6% 8.8% 13.9% 15.0% 
Colon and rectosigmoid 
junction 
1 2.1% 4.9% 4.5% 3.0% -1.5% -2.8% 
2 16.7% 15.9% 14.0% 14.7% 15.0% 4.8% 
3 29.9% 29.1% 29.2% 28.5% 30.2% 28.8% 
Kidney 1 2.1% 2.6% 6.0% 5.1% 0.5% -2.5% 
2 13.2% 17.0% 11.5% 16.1% 13.8% 26.4% 
3 19.8% 23.5% 25.7% 24.9% 23.5% 22.2% 
Larynx 1 11.5% 16.3% 19.0% 16.9% 11.2% 20.1% 
2 29.5% 29.5%* 20.5% 31.7% 32.3% 32.5%
3 33.9% 33.8%* 35.4% 34.2% 32.8% 20.7%
Lung (non-small cell) 1 5.4% 14.3% 25.4% 27.5% 29.6% 24.0% 
2 31.6% 34.2% 34.8% 34.5% 32.3% 29.6% 
3 35.7% 35.7% 34.1% 29.6% 27.9% 19.6% 
Melanoma of skin 1 1.1% 2.5% 0.4% 1.2% 0.2% 2.8% 
2 19.9% 22.5% 24% 28.2% 27.1% 34.4% 
3 29.0% 30.8% 31.4% 33.5% 31.4% 31.5% 
Oesophagus 1 31.6% 31.5% 29.8% 29.4% 24.7% 29.9%
2 35.9% 35.8%* 35.4% 34.3% 32.2% 28.3%
3 35.8% 34.2% 30.4% 31.9% 27.0% 25.3%
Ovary 1 4.6% 7.1% 10.8% 10.4% 11.3% -1.1% 
2 16.9% 26.2% 28.9% 29.6% 31.9% 35.3% 
3 31.5% 35.9% 33.8% 31.5% 28.6% 21.0% 
Pancreas 1 1.0%* 9.6%* 12.7% 15.4% 20.2%* 28.1%
2 23.8% 35.9%* 27% 23.6% 21.4% 25.9%
3 24.8% 24.7%* 32.3% 33.2%* 31.4%* 24.1%
Prostate 1 1.4%* 1.4% -0.3% -0.7% 1.6% 15.4% 
2 0.0%* -0.1% -0.3% -0.7% -1.5% 16.9%
3 0.0%* -0.1% -0.3% -0.7% -1.5% 17.8%
Stomach 1 12.2% 18.6%* 29.3% 21.4% 11.1% -6.5% 
2 35.0% 27.9%* 35.2% 34.4% 32.2% 18.0% 
3 35.0% 32.3% 33.2% 32.3% 28.9% 26.8% 
Uterus 1 3.3% 5.6% 6.1% 9.5% 12.6% 6.0% 
2 13.2% 18.4% 18.9% 26.5% 32.6% 33.0% 
3 10.2% 31.1% 33.4% 35.8% 33.1% 33.6% 
Table 2: Reduction in five-year net survival as a consequence of six-month delay to surgery 
for 13 cancer types, by tumour stage and age of diagnosis.  
Reduction in survival above the median is represented in red, at the median in yellow and below the median in 
green.  Survival analysis is based on per-day hazard ratios for disease fatality. * indicates strata estimates of 
lower confidence whereby crude rather than net survival estimates were applied.   
 
  
 Stage 30-39 40-49 50-59 60-69 70-79 80+ 
Bladder 
 
1 4.1* 3.3* 4.1 2.0 1.5 0.8 
2 0.7* 0.6 0.4 0.3 0.1 0.1 
3 0.7* 0.6* 0.4 0.3 0.2 0.1 
Breast (ER+, HER2-) 
 
1 0.3 0.1 0.0 -0.1 -0.2 -0.1 
2 1.2 0.5 0.3 0.1 -0.1 -0.2 
3 2.8 1.4 1.2 0.8 0.5 0.1 
Breast (ER-, HER2-) 
 
1 1.3 0.7 0.7 0.2 0.0 0.1 
2 2.7 2.0 1.4 0.9 0.7 0.4 
3 3.8* 3.3 2.4 1.6 1.0 0.5* 
Breast (HER2+) 1 0.1 0.2 0.1 0.0 -0.1 0.1 
2 0.9 0.5 0.4 0.3 0.2 0.2 
3 2.4 1.2 1.2 0.8 0.8 0.4 
Colon and rectosigmoid 
junction 
1 0.1 0.1 0.1 0.0 0.0 0.0 
2 0.6 0.4 0.3 0.2 0.1 0.0 
3 1.0 0.8 0.6 0.4 0.3 0.1 
Kidney 1 0.1 0.1 0.2 0.1 0.0 0.0 
2 0.5* 0.5 0.2 0.2 0.1 0.1 
3 0.7* 0.7 0.6 0.4 0.2 0.1 
Larynx 1 0.4* 0.4 0.4 0.2 0.1 0.1 
2 0.9* 0.7* 0.4* 0.4 0.3 0.1* 
3 1.0* 0.8* 0.6 0.4 0.3 0.1* 
Lung (non-small cell)  1 0.2 0.3 0.5 0.3 0.2 0.1 
2 0.9* 0.8 0.6 0.4 0.2 0.1 
3 1.1* 0.8 0.6 0.4 0.2 0.1 
Melanoma of skin 1 0.4 0.7 0.1 0.2 0.0 0.1 
2 2.1 1.9 1.5 1.2 0.7 0.5 
3 3.0 2.6 2.0 1.5 0.9 0.4 
Oesophagus 1 0.6* 0.4 0.3 0.2 0.1 0.1* 
2 0.6* 0.5* 0.4 0.3 0.1 0.1* 
3 0.6* 0.5 0.3 0.2 0.1 0.1* 
Ovary 1 0.5 0.6 0.7 0.5 0.3 0.0 
2 1.8* 2.2 1.8 1.3 0.9 0.5 
3 0.8 0.8 0.5 0.4 0.2 0.1 
Pancreas 1 0.0* 0.1* 0.1* 0.1 0.1* 0.1* 
2 0.4* 0.5* 0.3 0.2 0.1 0.1* 
3 0.4* 0.4* 0.4* 0.3* 0.1* 0.1* 
Prostate 1 0.0* 0.0 0.0 0.0 0.0 0.1 
2 0.0* 0.0 0.0 0.0 0.0 0.1* 
3 0.0* 0.0 0.0 0.0 0.0 0.1* 
Stomach 1 0.3* 0.3* 0.4 0.2 0.1 0.0 
2 0.7* 0.4* 0.4 0.3 0.2 0.0 
3 0.7* 0.5 0.4 0.3 0.1 0.1 
Uterus 1 0.3 0.4 0.3 0.4 0.3 0.1 
2 1.1* 1.3 1.0 1.0 0.7 0.4 
3 0.9* 2.2 1.8 1.3 0.8 0.4 
Table 3: Estimated average life years gained per unit of healthcare resource for cancer 
surgery for 13 cancer types, by tumour stage and age of diagnosis comparing current 
surgery to surgery after six months delay based on 5-year net survival.  
* indicates strata estimates of lower confidence whereby crude rather than net survival estimates were 
applied. Values for LYG per HCRU above the median are represented in blue, at the median in white and below 
the median in red. 
 
 
  
Table 4: Summary outcomes from delays in cancer surgery, with comparison to an 
equivalent number of admissions for community-acquired COVID-19 infection.  Only major 
resections for common adult cancers included. Reference population:  England. LY: life 
years.  RALY: resource adjusted life years. HCRU: healthcare resource units 
3 6 3 6
4,755 10,760 9,511 21,521
92,214 208,275 184,428 416,549
17.1 15.9 17.1 15.9
0.97 2.19 0.97 2.19
2.12 1.97 2.12 1.97
0.12 0.27 0.12 0.27
Total admissions
ICU admissions
non-ICU admissions
Total
ICU
non-ICU
Total
ICU
non-ICU
All
ICU
non-ICU
All
ICU
non-ICU
All
ICU
non-ICU
All
ICU
non-ICU
19% 43% 19% 43%
26% 59% 26% 59%
12 24
5%
18.1
2.2
Reference time period (months)
HCRUs-total
LY gained-total
Lives saved-total
LY gained from cancer 
78,777 157,553
STANDARD 
CONDITIONS
IMPACT of 
DELAY
CANCER SURGERY
Per patient delay (months)
Per day rate of nosocomial infection (current)
HOSPITALISATION OF COMMUNITY-ACQUIRED COVID INFECTION
Reference time period (months) 12 24
683,083 1,366,167
94,912 189,823
16,135 32,270
1,052,949 2,105,899
556,657 1,113,313
496,293 992,586
15,587 31,173
8,241 16,481
7,346 14,692
25,752 51,504
7,894 15,789
17,858 35,715
80,406 160,812
Major resections for cancer-
0.52
Total LY gained
-attributable to hospital 
admission
5.08
13.83
3.29
0.46
0.40
482,022 964,044
223,227 446,454
258,795 517,591
94,912 189,823
764,765 1,529,529
1,717,051 3,434,102
LY gained from cancer 
Deaths attributable to delay-
total
LY lost attributable to delay-
total
LY gained from cancer 
treatment post-delay- average 
per patient
LY lost attributable to delay-
average per patient
LY gained 
-average per patient
LY gained per HCRU 
-average per patient
LY lost through delay in cancer 
treatment as a proportion of LY 
gaineds from hospitalisation 
from COVID-19
RALY lost through delay in 
cancer treatment as a 
proportion of RALY gaineds 
from hospitalisation from 
COVID-19
LY gained per HCRU from 
cancer treatment post-delay- 
average per patient
LY lost per HCRU attributable 
to delay-average per patient
Hospital Admissions
Health care resource 
units (HCRUs)
Deaths
Total lives saved
-attributable to hospital 
admission
Comparison
Community infections
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